No profile data available.
Odonate, Inc. (ODTC) is a healthcare company in the breast cancer treatment drugs industry, based in New York, United States, with about 137 full-time employees.
It reported revenue of $0 for fiscal year 2023, and net income of $7.33 million. Its market capitalization was $53.40 million as of February 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2023; market data as of February 4, 2025.
, has no significant operations. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
Odonate reported $0 in revenue for fiscal year 2023.
$53.40 million as of February 4, 2025.
Listed companies of a similar size in the same industry (breast cancer treatment drugs) include Olema Pharmaceuticals, Inc. (OLMA), Puma Biotechnology, Inc. (PBYI), Greenwich LifeSciences, Inc. (GLSI), BriaCell Therapeutics Corp. (BCTX).